TY - JOUR
T1 - Differences in liver pathology and clinical outcome between two patients with Hepatitis B virus and graft versus host disease
AU - Üstün, Celalettin
AU - Özcan, Muhit
AU - Gürman, Günhan
AU - Çakir, Mehtap
AU - Erekul, Selim
AU - Akyol, Gülen
AU - Arat, Mutlu
AU - Çelebi, Harika
AU - Idlman, Ramazan
AU - Ilhan, Osman
AU - Demirer, Taner
AU - Beksaç, Meral
AU - Koç, Haluk
PY - 1999/9
Y1 - 1999/9
N2 - Our two patients undergoing allogeneic bone marrow transplantation (AlloBMT) had both Hepatitis B virus (HBV) and graft-versus-host disease (GVHD). In the first patient, liver enzymes elevated three months after AlloBMT, and GVHD was diagnosed. Two weeks after the diagnosis of GVHD, HBsAg appeared in his serum. At that time, liver biopsy was not able to discriminate two disorders, but his sequential liver biopsies disclosed GVHD. Despite the patient was treated with cyclosporin A (CsA), he died for chronic GVHD. In contrast to the first patient, the second patient had HBsAg prior to GVHD. His liver enzymes deterioration was detected in the first month after AlloBMT, and reached the highest level in the third month while withdrawing CsA. In the fifth month he developed scleradermatous skin changes, and skin biopsy revealed chronic GVHD, whereas concurrent liver biopsy revealed chronic active hepatitis. This observation showed that immunosuppressive conditions such as GVHD or its prophylaxis may affect the appearance of liver pathology caused by HBV, which depends on the time of GVHD development, and the duration and depth of GVHD prophylaxis.
AB - Our two patients undergoing allogeneic bone marrow transplantation (AlloBMT) had both Hepatitis B virus (HBV) and graft-versus-host disease (GVHD). In the first patient, liver enzymes elevated three months after AlloBMT, and GVHD was diagnosed. Two weeks after the diagnosis of GVHD, HBsAg appeared in his serum. At that time, liver biopsy was not able to discriminate two disorders, but his sequential liver biopsies disclosed GVHD. Despite the patient was treated with cyclosporin A (CsA), he died for chronic GVHD. In contrast to the first patient, the second patient had HBsAg prior to GVHD. His liver enzymes deterioration was detected in the first month after AlloBMT, and reached the highest level in the third month while withdrawing CsA. In the fifth month he developed scleradermatous skin changes, and skin biopsy revealed chronic GVHD, whereas concurrent liver biopsy revealed chronic active hepatitis. This observation showed that immunosuppressive conditions such as GVHD or its prophylaxis may affect the appearance of liver pathology caused by HBV, which depends on the time of GVHD development, and the duration and depth of GVHD prophylaxis.
KW - AlloBMT
KW - Graft versus-host disease
KW - Hepatitis B virus
UR - http://www.scopus.com/inward/record.url?scp=0344500846&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0344500846&partnerID=8YFLogxK
U2 - 10.1053/paor.1999.0229
DO - 10.1053/paor.1999.0229
M3 - Article
C2 - 10491023
AN - SCOPUS:0344500846
SN - 1219-4956
VL - 5
SP - 229
EP - 232
JO - Pathology and Oncology Research
JF - Pathology and Oncology Research
IS - 3
ER -